VivoSeq
Oncology

B-Cell Neoplasm

9

Pipeline Programs↗

6

Active Trials↗

4

Companies Involved↗

B-cell neoplasm is an early-stage landscape with 9 programs across 4 companies. The most active players are Genmab, Johnson & Johnson, Roche.

Intelligence

Pipeline Metrics

Competitive Density

38/100

Pipeline Velocity

15/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Genmab logo

Genmab

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1Roche logo

Roche

1 program

PreclinicalAkero Therapeutics logo

Akero Therapeutics

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

10programs
Small molecule550%
Antibody–drug conjugate220%
Cell therapy220%
Monoclonal antibody110%

Modality classified for 100% of 10 pipeline programs.

Analysis

Trial Status

9

clinical trials

Recruiting3 · 33%
Completed3 · 33%
Not yet recruiting2 · 22%
Active, not recruiting1 · 11%

Clinical Trials

Trial Activity

9 trials

Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
Recruiting·MMiltenyi Biomedicine GmbH·Phase 2·NCT06508931·31 enrolled
Study of SGR-1505 in Mature B-Cell Neoplasms
Recruiting·SSchrödinger, Inc.·Phase 1·NCT05544019·98 enrolled
Prospective, Observational, Multi-centred, Non-interventional Research Project on Plasma Cell Free DNA Genotyping as a Tool to Inform Mature B-cell Tumor Management
Recruiting·OOncology Institute of Southern Switzerland·N/A·NCT03280394·444 enrolled
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Active, not recruiting·Genmab logoGenmab·Phase 1·NCT05206357·17 enrolled
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07234045·30 enrolled
A Clinical Study to Explore CT1194D in Patients With Relapsed/Refractory B-Cell Neoplasms
Not yet recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1·NCT07200479·20 enrolled
A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Completed·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT01704963·15 enrolled
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
Completed·National Cancer Institute (NCI)·Phase 1·NCT00082784·93 enrolled
A Study of Hutchison MediPharma Limited(HMPL)-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
Completed·HHutchison Medipharma Limited·Phase 1·NCT02857998·134 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)